N,N-bis[3-(t-butoxycarbonylamino)propyl]acetamide | 490025-51-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,N-bis[3-(t-butoxycarbonylamino)propyl]acetamide
• 英文别名: di-tert-butyl ((acetylazanediyl)bis(propane-3,1-diyl))dicarbamate；tert-butyl N-[3-[acetyl-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]amino]propyl]carbamate
• CAS: 490025-51-9
• 化学式: C₁₈H₃₅N₃O₅
• 分子量: 373.493
• InChiKey: SIJPNGPUMYJFJI-UHFFFAOYSA-N

物化性质

• 沸点：
  526.4±35.0 °C(Predicted)
• 密度：
  1.052±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  26
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  97
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N,N-bis[3-(t-butoxycarbonylamino)propyl]acetamide 在 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 戊醇 为溶剂， 反应 17.0h， 生成 N,N-bis[3-(1,2,3,4-tetrahydroacridin-9-ylamino)propyl]acetamide
  参考文献：
  名称：

  Specific Targeting of Acetylcholinesterase and Butyrylcholinesterase Recognition Sites. Rational Design of Novel, Selective, and Highly Potent Cholinesterase Inhibitors

  摘要：

  Tacrine-based AChE and BuChE inhibitors were designed by investigating the topology of the active site gorge of the two enzymes. The homobivalent ligands characterized by a nitrogen-bridged atom at the tether level could be considered among the most potent and selective cholinesterase inhibitors described to date. The nitrogen-containing homobivalent ligands 3e,g and the sulfur-containing 3h validated the hypothesis of extra sites of interaction in the AChE and BuChE active site gorges.

  DOI：

  10.1021/jm0255668
• 作为产物：
  描述：

  3,3'-二氨基二丙基胺 在 氢氧化钾 、 TEA 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 8.0h， 生成 N,N-bis[3-(t-butoxycarbonylamino)propyl]acetamide
  参考文献：
  名称：

  Specific Targeting of Acetylcholinesterase and Butyrylcholinesterase Recognition Sites. Rational Design of Novel, Selective, and Highly Potent Cholinesterase Inhibitors

  摘要：

  Tacrine-based AChE and BuChE inhibitors were designed by investigating the topology of the active site gorge of the two enzymes. The homobivalent ligands characterized by a nitrogen-bridged atom at the tether level could be considered among the most potent and selective cholinesterase inhibitors described to date. The nitrogen-containing homobivalent ligands 3e,g and the sulfur-containing 3h validated the hypothesis of extra sites of interaction in the AChE and BuChE active site gorges.

  DOI：

  10.1021/jm0255668

文献信息

• Probing the mid-gorge of cholinesterases with spacer-modified bivalent quinazolinimines leads to highly potent and selective butyrylcholinesterase inhibitors
  作者：Xinyu Chen、Irina G. Tikhonova、Michael Decker

  DOI：10.1016/j.bmc.2010.12.034

  日期：2011.2

  The spacer structure of homobivalent quinazolinimes acting as potent acetyl-(AChE)- and butyrylcholinesterase (BChE) inhibitors was chemically modified introducing tertiary amine and acyl-amide moieties, and the activities at both ChEs were evaluated. Molecular docking was applied to explain the data and probe the capacity of the mid-gorge site of both ChEs. The novel spacer structures considerably alter the biological profile of bivalent quinazolinimines with regard to both inhibitory activity and selectivity. Mutual interaction of binding to the various sites of the enzymes was further investigated by applying also different spacer lengths and ring sizes of the alicycle of the tricyclic quinazolinimines. In order to achieve selectivity toward BChE and to improve inhibitory activities, the spacer structure was optimized and identified a highly potent and selective BChE inhibitor. (C) 2010 Elsevier Ltd. All rights reserved.
• ANTIMICROBIAL CONJUGATES, METHOD FOR PRODUCTION AND USES THEREOF
  申请人：The Secretary of State for Health

  公开号：US20170144969A1

  公开（公告）日：2017-05-25

  The present disclosure relates to polyamine conjugates, its isomers, prodrugs and pharmaceutically acceptable salts thereof. The present disclosure also relates to process of preparation of polyamine conjugates, its stereoisomers, prodrugs, pharmaceutically acceptable salts thereof, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases mediated by microbes.